Fulcrum Therapeutics Inc (FULC)
3.02 -0.09 (-2.89%) 14:25 ET [NASDAQ]
3.01 x 106 3.03 x 300
Realtime by (Cboe BZX)
3.01 x 106 3.03 x 300
Realtime - - (-) -
for Wed, Mar 26th, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
Cash Flows From Operating Activities | |||||
Net Income | -9,725 | -97,335 | -109,872 | -80,847 | -70,819 |
Depreciation Amortization | 1,593 | 2,172 | 2,414 | 2,515 | 2,379 |
Accounts receivable | -1,559 | -308 | 3,408 | -1,106 | -2,531 |
Accounts payable and accrued liabilities | -1,593 | -853 | -1,176 | 973 | 1,773 |
Other Working Capital | -4,248 | -4,613 | -3,094 | -11,889 | 7,503 |
Other Operating Activity | 13,314 | 9,972 | 11,270 | 11,876 | 8,040 |
Operating Cash Flow | $-2,218 | $-90,965 | $-97,050 | $-78,478 | $-53,655 |
Cash Flows From Investing Activities | |||||
Change In Deposits | 32,508 | -36,184 | 14,376 | -127,956 | -55,796 |
PPE Investments | -278 | -508 | -1,963 | -1,713 | -1,342 |
Investing Cash Flow | $32,230 | $-36,692 | $12,413 | $-129,669 | $-57,138 |
Cash Flows From Financing Activities | |||||
Debt Repayment | N/A | N/A | N/A | -18 | -50 |
Common Stock Issued | 2,746 | 118,122 | 84,323 | 186,525 | 71,375 |
Other Financing Activity | 0 | 0 | 0 | 0 | -193 |
Financing Cash Flow | $2,746 | $118,122 | $84,323 | $186,507 | $71,132 |
Beginning Cash Position | 26,655 | 36,190 | 36,504 | 58,144 | 97,805 |
End Cash Position | 59,413 | 26,655 | 36,190 | 36,504 | 58,144 |
Net Cash Flow | $32,758 | $-9,535 | $-314 | $-21,640 | $-39,661 |
Free Cash Flow | |||||
Operating Cash Flow | -2,218 | -90,965 | -97,050 | -78,478 | -53,655 |
Capital Expenditure | -278 | -508 | -1,963 | -1,713 | -1,342 |
Free Cash Flow | -2,496 | -91,473 | -99,013 | -80,191 | -54,997 |